Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Octreotide microspheres

Phase 3Small molecule

SShanghai Zhongshan Hospital

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic FistulaNot yet recruiting

Pancreatic FistulaPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q2 2028

Not yet recruiting

Neuroendocrine Tumors

NCT06300216

Q4 2028

Phase 3Not yet recruiting

Pancreatic Fistula

NCT07479784

Clinical

Trials by Indication[1]

Pancreatic Fistula1 trial

Octreotide Microspheres for Preventing Pancreatic Fistula

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 3·NCT07479784·230 enrolled

Neuroendocrine Tumors1 trial

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Not yet recruiting·QQilu Hospital of Shandong University··NCT06300216·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Octreotide microspheres. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Octreotide microspheres compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Octreotide microspheres. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Zhongshan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Zhongshan Hospital

Related News